IMI2 – CALLS 22 AND 23: FUTURE TOPICS
"PROPOSED TOPIC 2 : MODELLING THE IMPACT OF MONOCLONAL ANTIBODIES AND VACCINES ON THE REDUCTION OF ANTIMICROBIAL RESISTANCE"
Indicative open date : 23 June 2020
Submission Deadline : TBD
Action type: Research and Innovation Action (RIA)
The draft topics have been sent to the Governing Board for approval. The final versions of the topic texts, as well as details of how to apply, will be published at Call launch.
webinars on the Calls are open:
Registration is now open for the webinars on the Calls held from 15 to 30 June. Registration is free but obligatory.
IMI2 – Call 22:
Single-stage Call for proposals designed to support research activities that will build on, and add value to, results from certain ongoing IMI2 projects.
IMI2 – Call 23:
Standard, two-stage Call for proposals with the following topics:
- Returning clinical trial data to study participants within a GDPR compliant and approved framework.
- Modelling the impact of monoclonal antibodies and vaccines on the reduction of antimicrobial resistance. This topic is part of IMI’s Antimicrobial Resistance (AMR) Accelerator programme.
- A platform for accelerating biomarker discovery and validation to support therapeutics development for neurodegenerative diseases.
- Optimal treatment for patients with solid tumours in Europe through artificial intelligence.
- Shortening the path to rare disease diagnosis by using new born genetic screening and digital technologies.
- Behavioural model of factors affecting patient adherence.
The updated draft texts are available on the IMI Future Topics page.
